HBOT and the Pharmaceutical Industry: Why a Non Drug Therapy Faces Structural Headwinds

Hyperbaric oxygen therapy is not a drug. It cannot be patented, bottled, or sold through a pharmacy. A course of treatment uses pressurised air and oxygen, both of which are freely available and unownable. That single fact has more influence over the therapy's position in mainstream medicine than almost any clinical consideration, and understanding it helps explain why a therapy with a substantial and growing evidence base remains largely outside the commercial infrastructure that drives medical research and adoption.

This is not a conspiracy. It is a structural reality. The pharmaceutical industry operates within a commercial logic that requires a return on investment, and HBOT does not offer one. The consequences of that misalignment are worth examining clearly.

How Drug Development Gets Funded

The development of a new pharmaceutical compound is extraordinarily expensive. Estimates for the full cost of bringing a drug from discovery to regulatory approval, including the cost of failed trials, typically run into the billions. That investment is only viable if the resulting product can be protected by intellectual property, sold at a margin, and prescribed at scale over a long period.

Patent protection is the mechanism that makes this model work. A company that develops a new compound can hold exclusive rights to manufacture and sell it for a defined period, during which it can recover its investment and generate profit. That profit then funds the next round of research and development.

HBOT has no equivalent mechanism. Oxygen under pressure cannot be patented. The chambers used to deliver treatment are manufactured by a range of companies, none of which has a monopoly on the therapy itself. A clinic that invests in an HBOT programme cannot prevent a competitor from offering the same treatment. There is no proprietary molecule, no exclusive formulation, and no mechanism for capturing the value of a successful clinical outcome in the way that pharmaceutical companies can.

The result is that the commercial incentive to fund large scale HBOT trials simply does not exist in the same way it does for drug development. The entities that would normally drive that investment have no financial reason to do so.

What This Means for the Evidence Base

Clinical trials are expensive. The gold standard, a large randomised controlled trial with a placebo arm, rigorous blinding, and long term follow up, can cost tens of millions of dollars. For pharmaceutical compounds, that cost is typically borne by the manufacturer, who has a direct financial interest in a positive outcome and the resources to fund the work.

For HBOT, that funding model does not apply. Research has been driven largely by academic institutions, military and veterans health programmes, and a small number of dedicated hyperbaric medicine centres. The work coming out of groups like the Sagol Center in Israel, the Hyperbaric Medical Unit at Assaf Harofeh, and various military research programmes has been genuinely significant. But it has been produced without the industrial scale investment that pharmaceutical trials attract, and that shows in the evidence base.

The trials are often smaller than regulators and guideline committees would prefer. Protocols vary between studies, making direct comparison difficult. Independent replication, which is essential for building consensus, has been slower than the pace of initial findings. None of this reflects a problem with the underlying science. It reflects a funding gap that is structural rather than scientific.

When physicians or regulators point to the evidence base for HBOT in conditions like traumatic brain injury, long COVID, or cognitive decline as insufficient, they are often applying a standard that was designed for a research environment where industrial funding is available. HBOT has not had access to that environment, and the comparison is not entirely fair.

The Regulatory Pathway Problem

Drug approval follows a well established pathway. A company submits clinical trial data to a regulatory body, which evaluates the evidence against defined criteria and either approves or rejects the application. That pathway is expensive and demanding, but it is clear, and companies have strong incentives to navigate it because approval unlocks a protected commercial market.

HBOT does not have a comparable incentive structure for pursuing expanded regulatory approval. The therapy is already approved for a defined set of indications in most jurisdictions, and those approvals allow it to be practised legally. Pursuing additional approvals for conditions like neurological recovery or post viral syndromes would require funding large scale trials, navigating a complex regulatory process, and producing a result that any hyperbaric facility could then use without compensating the entity that funded the work.

No commercial entity has a strong reason to fund that process. Academic institutions and government bodies can and do contribute, but they operate on different timelines and with different resource constraints than pharmaceutical companies. The result is that the regulatory approval of HBOT for emerging indications lags behind the evidence, not because the evidence is absent, but because the mechanism for converting evidence into approval is misaligned with the therapy's commercial structure.

The Reimbursement Consequence

Regulatory approval and insurance reimbursement are closely linked. In most healthcare systems, reimbursement decisions follow regulatory guidance. If a therapy is not approved for a given indication, it is typically not reimbursable for that indication, regardless of what the evidence suggests.

For HBOT, this creates a practical barrier that affects patient access in a direct and significant way. A patient with a condition for which HBOT has meaningful supporting research, but which falls outside the approved indications, will generally find that their insurer will not cover the cost of treatment. The cost then falls to the patient, which places HBOT outside the reach of many people who might benefit from it.

This is not a deliberate exclusion. It is the downstream consequence of a funding and approval structure that was not designed with non drug therapies in mind. The reimbursement system reflects the evidence that has been formally submitted and approved, and the evidence that has been formally submitted and approved reflects the commercial incentives that drive research investment. HBOT sits outside that loop.

Where Investment Does Flow

It is worth noting where pharmaceutical investment does flow in relation to conditions for which HBOT has shown promise. Neurological conditions, post viral syndromes, cognitive decline, and wound healing are all areas of active pharmaceutical research. Compounds targeting inflammation, neuroplasticity, mitochondrial function, and tissue repair are in various stages of development and trial.

Some of those compounds address mechanisms that HBOT also engages, including the stimulation of stem cell mobilisation, the modulation of inflammatory pathways, and the promotion of angiogenesis. The difference is that a pharmaceutical compound addressing those mechanisms can be patented and commercialised. HBOT, which engages many of the same pathways through a different mechanism, cannot.

This does not mean pharmaceutical research in these areas is without value. It means that the commercial logic of the industry directs investment toward patentable solutions, and that non patentable therapies with overlapping mechanisms receive comparatively little attention regardless of their clinical potential.

What Patients Should Understand

None of this means that HBOT is a suppressed therapy or that the pharmaceutical industry is engaged in active opposition to its development. The dynamic is more mundane and more structural than that. HBOT simply does not fit the commercial model that drives pharmaceutical investment, and the consequences of that misfit play out across research funding, regulatory approval, and reimbursement in ways that affect patient access.

For patients navigating this landscape, the practical implication is that the absence of pharmaceutical industry backing for HBOT does not reflect a clinical judgement about the therapy's value. It reflects a commercial judgement about the therapy's profitability. Those are different things, and conflating them leads to a distorted picture of what the evidence actually supports.

The evidence for HBOT in a range of conditions is real, growing, and in some areas compelling. Accessing that evidence, understanding what it does and does not support, and identifying the clinical contexts in which HBOT is most likely to be relevant requires guidance from people who understand both the science and the structural environment in which it operates.

That is the kind of informed navigation that makes a genuine difference for patients who are trying to make sense of a therapy that the mainstream commercial infrastructure of medicine has not been designed to support.